Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company’s lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key …

Read more on News-Medical-Net

Additional reading:

1. Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP …
   
   Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP … Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease,...


2. ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer
   
   ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically – determined administration of...